

Transcriptional and epigenetic mechanisms in cancer and cancer immunotherapy

Anjana Rao


La Jolla Institute for Immunology

Sanford Consortium for Regenerative Medicine

Department of Pharmacology and Moores Cancer Centre, UCSD



Transcriptional states of CD8⁺ T cells during immune responses




What transcription factors contribute to T cell “exhaustion”?

The cooperative NFAT:AP-1 complex

T cell nuclear extracts

Steve Harrison
Lin Chen

Patrick Hogan




- NFAT:Fos:Jun:DNA (1 nM Kd)
- NFAT:DNA (20 nM Kd)

free DNA probe
ARRE site of mouse IL-2 promoter
TGGAAAACTGTTTCA

Jugnu Jain
Pat McCaffrey

Patrick Hogan



GGAAAAAC TGTTC A


L Chen et al., *Nature* 1998

Jain et al., *Nature* 1993; McCaffrey et al., *Science* 1993

Rao, Luo and Hogan, *Annu Rev Immunol* 1997; Hogan et al., *G&D* 2003


Does NFAT have different biological functions with and without AP-1?

PMA + ionomycin (surrogate for TCR + costimulation)




~1100 activation-associated genes: IL2, IL3, IL4, IL5, IFN γ , GMCSF, CD40L, etc

ionomycin alone (surrogate for TCR without costimulation)




~150 anergy-associated genes (negative regulators): inhibitory cell-surface receptors
 tyrosine phosphatases, diacylglycerol kinase, E3 ubiquitin ligases: Itch, Cbl-b, Grail
 transcriptional repressors: Ikaros, Jumonji
 LAT palmitoyl transferase

Time course of NFAT and AP-1 (Fos-Jun) activation after stimulation




Oh-hora et al., *Nature Immunol*/2008



AP-1 components
(Fos and Jun family members)
are transiently activated

Jain et al., *J Immunol*/1993



A negative feedback mechanism is turned on at the later stages of T cell activation by NFAT without AP-1, and initiates the transcriptional program of T cell hyporesponsiveness ("tolerance/ anergy/ exhaustion/ dysfunction")


This represents the end stage of a physiological (esp. chronic) immune response: hyporesponsiveness to further stimulation through the TCR (minimal Ca influx, diminished cytokine production)

Later reinforced by epigenetic mechanisms that stabilise the "exhausted" state

NFAT without AP-1 → decreased IL-2 production, upregulation of inhibitory receptors



Fernando Macián



Gustavo Martinez
Renata Pereira

CA-RIT-NFAT1 (R>A, I>A, T>G) = constitutively active NFAT1 that cannot cooperate with AP-1

Retrovirally introduce CA-RIT-NFAT1 into CD4⁺ and CD8⁺ T cells (i.e. initiate the inhibitory program before the activation program):

- decreased cytokine production, increased expression of inhibitory receptors
- decreased tumour rejection in a mouse model in vivo
- decreased ability to combat *Listeria* infection in vivo
- resemble “exhausted” CD8⁺ T cells by transcriptional profiling and ATAC-seq

Macián et al., EMBO J 2000; Macián et al., *Cell* 2002; Martinez et al., *Immunity* 2015

- The same transcription factor, NFAT, induces different transcriptional programs in the same cells: activation when AP-1 is present, hyporesponsiveness later when AP-1 has died away
- a constitutively active NFAT that cannot cooperate with AP-1 induces the hyporesponsive programme in transduced CD4⁺ as well as CD8⁺ T cells (decreased cytokine production, expression of several inhibitory surface receptors, attenuated immune responses)


Macián et al., *EMBO J* 2000; Macián et al., *Cell* 2002; Martinez et al., *Immunity* 2015

Does endogenous NFAT function in the same way?

Three model systems to study CD8⁺ T cell exhaustion:


1. **LCMV chronic infection model:** James Scott-Browne, Renata Pereira
2. **B16-OVA and OT-I anti-tumor response model:** Sara Trifari, Giuliana Mognol
3. **CAR-T cell model to examine effects of complex gene deletions:** Joyce Chen

LCMV model: RNA-seq



Renata Pereira

Naive
Effector
Memory
Exhausted





Tox Tox2 Nr4a2 Nr4a1



James Scott-Browne

B16-OVA model of anti-tumor response



Sara Trifari




Giuliana Mognol
(Patrick Hogan's lab)




Victor Wong

Bioinformatics: Roberto Spreafico, Alex Hoffmann (UCLA)




Transcription factors & chromatin associated enzymes




Mognol et al., *PNAS* 2017


Experimental system to define the roles of candidate proteins in CD8⁺ T cell exhaustion




Joyce Chen






~97% transduction efficiency of CAR-2A-Thy1.1 into CD8⁺ T cells




Generation of huCD19-expressing target cells




Schematic of CAR model and isolation of tumor-infiltrating lymphocytes (TILs)



Volcano plots of RNA-seq data: differentially expressed genes




Reason to examine TOX and TOX2:
Nr4a, *Tox* and *Tox2* gene loci display “exhaustion”-specific accessible regions that contain “NFAT without AP-1” motifs



Reason to examine NR4A:
Differentially-accessible regions in each of these “exhausted” cell types are enriched for consensus binding motifs for nuclear receptors including NFAT and NR4A


ATAC-seq (B16-OVA model):

Nr4a2 binds accessible chromatin regions specific to "exhausted" cells (B16-OVA model)



Are the tumour-infiltrating cells a uniform population or a mixture of activated and "exhausted" cells? Single-cell analyses ...

Exhaustion-specific accessible regions in the *Tox2* gene



NR4A: a family of orphan nuclear receptors

NR4A1 = Nur77, NGFI- β

NR4A2 = Nurr1

NR4A3 = Nor1



NR4A family members exhibit functional redundancy



- NR4A triple knockout mice have severe defects in T regulatory cell development but mice lacking just two NR4A family members are less affected or not affected at all

Sekiya T, et al. *Nat. Commun.* 2011; Saijo K, et al. *Cell*, 2009; Sekiya T, et al. *Nat. Immunol.* 2013


Donor	Genotype	Retrovirus 1	Retrovirus 2
PBS	n/a	none	none
WT	<i>Nr4a1 fl/fl Nr4a2 fl/fl Nr4a3 +/+</i>	CAR	empty vector
Nr4a TKO	<i>Nr4a1 fl/fl Nr4a2 fl/fl Nr4a3 -/-</i>	CAR	Cre
Nr4a1 KO	<i>Nr4a1 fl/fl Nr4a2 +/+ Nr4a3 +/+</i>	CAR	Cre
Nr4a2 KO	<i>Nr4a1 +/+ Nr4a2 fl/fl Nr4a3 +/+</i>	CAR	Cre
Nr4a3 -/-	<i>Nr4a1 fl/fl Nr4a2 fl/fl Nr4a3 -/-</i>	CAR	empty vector

Collaboration with Dr. Takashi Sekiya and Dr. Akihiko Yoshimura, Keio University, Japan

Triple Nr4a-deficient CAR TILs → tumour regression & prolonged survival



CAR TILs deficient in both TOX and TOX2 potentiate tumour regression more effectively than CAR TILs deficient in either TOX family member alone






Hyungseok Seo


Avinash Bhandoola, Patrick Hogan

H Seo et al., *PNAS* 2019



CAR TILs deficient in both TOX and TOX2 potentiate tumour regression more effectively than CAR TILs deficient in either TOX family member alone




TOX DKO CAR TILs showed decreased expression of inhibitory receptors, increased cytokine expression and increased cytolytic activity; decreased TCF1, Eomes; no change in TBET



TOX DKO > WT



WT > TOX DKO




In both *NR4A TKO* and *TOX/TOX2 DKO* TILs:

Genomic regions that are more accessible in *TOX DKO* compared to WT TILs are enriched for consensus binding motifs for NFκB and bZIP transcription factors, both associated with T cell activation

Summary

- NFAT induces NR4A, TOX and other transcription factors in exhausted CD8⁺ T cells
- Deletion of NR4A or TOX family members “reverses” exhaustion and induces tumor regression
- Deletion of NR4A or TOX induces increased accessibility of regions that bind bZIP and NFκB transcription factors relevant to T cell activation



LCMV


B16-OVA – P14 and OVA



James Scott-Browne



Renata Pereira



Sara Trifari



Victor Wong



Giuliana Mognol

CAR-T cells – NR4A

CAR-T – TOX & TOX2, TET



Joyce Chen



Isaac López Moyado



Hyungseok Seo

@AnjanaRaoLab

Edahí González-Avalos
Daniela Samaniego-Castruita

JSB

Collaborators:

Patrick Hogan, La Jolla Institute

Akihiko Yoshimura and Takashi Sekiya, Keio University, Japan

Avinash Bhandoola, National Cancer Institute, National Institutes of Health, USA

Li-Fan Lu, UCSD